Clozapine
Code | Size | Price |
---|
TAR-T0455-50mg | 50mg | £124.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0455-100mg | 100mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0455-200mg | 200mg | £210.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0455-500mg | 500mg | £333.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0455-1g | 1g | £470.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Clozapine is a tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity.
CAS:
5786-21-0
Formula:
C18H19ClN4
Molecular Weight:
326.83
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9993
SMILES:
CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12
Target:
Dopamine Receptor; Adrenergic Receptor; AChR
References
1. Robertson GS, et al. Neuroscience, 1992, 46(2), 315-328.
2. Nguyen TV, et al. Proc Natl Acad Sci U S A, 1992, 89(10), 4270-4274.
3. Brunello N, et al. Neuropsychopharmacology, 1995, 13(3), 177-213.
4. Arvanov VL, et al. J Pharmacol Exp Ther, 1997, 283(1), 226-234.
5. Zorn SH, et al. Eur J Pharmacol, 1994, 269(3), R1-2.